For this reason, it was felt that further guidance was required. However, despite these advances, there are still patients who do not respond to treatment with anti-TNF therapies and there are difficult clinical situations where the risks of such drugs may outweigh the benefits of therapy. Since then, their use in PsA has become more widespread, with multiple anti-TNF drugs licensed for the treatment of PsA and approved for therapy by the National Institute for Health and Clinical Excellence (NICE).
At that time only one of the anti-TNF therapies was licensed for the treatment of PsA. The last British Society of Rheumatology (BSR) guidelines for the treatment of PsA were published in 2005 when anti-TNF therapy was not widely available. The use of anti-TNF therapy for the treatment of inflammatory arthritis, including PsA, has revolutionized therapeutic options in rheumatology. It is considered a type of seronegative spondyloarthritis and can cause arthritis, enthesitis, dactylitis and axial inflammation. PsA is a chronic inflammatory arthropathy affecting up to 40% of patients with skin or nail psoriasis. Psoriatic arthritis, biologics, treatment, management, guidelines, recommendations, anti-TNF therapies, psoriasis, enthesitis, dactylitis Executive summary Background of the disease
0 kommentar(er)
